DSP-7888
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Diffuse Intrinsic Pontine Glioma
Trial Timeline
Apr 1, 2016 → Jan 1, 2020
NCT ID
NCT02750891About DSP-7888
DSP-7888 is a phase 1/2 stage product being developed by Sumitomo Pharma for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02750891. Target conditions include Glioblastoma, Diffuse Intrinsic Pontine Glioma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02750891 | Phase 1/2 | Completed |
| NCT02436252 | Phase 1/2 | Completed |
Competing Products
20 competing products in Glioblastoma